Nexilico
Nexilico, Inc.: An R&D startup advancing microbiome research and precision medicine through predictive computational platforms.
Founded
2019Nexilico, Inc.: An R&D startup advancing microbiome research and precision medicine through predictive computational platforms.
Nexilico, Inc. is an early-stage biotechnology startup founded with the mission to advance microbiome and precision medicine research. The company focuses on developing next-generation predictive computational platforms that enhance drug design, development, and therapeutic clinical outcomes. By leveraging computational biology and AI, Nexilico aims to address complex challenges in medicine and biotechnology, particularly those related to the role of microbiomes in health and disease.
Nexilico has attracted attention from notable figures in the biotechnology and computational biology sectors, as well as early-stage investors interested in cutting-edge medical technologies. The startup's key achievements include pioneering in silico microbiome technologies that have significantly advanced scientific understanding and practical applications in precision medicine. Nexilico's impact lies in its potential to revolutionize how microbiome-related diseases are treated and how new therapeutics are developed, promising significant improvements in patient outcomes.
Companies similar to Nexilico include Selva, BrilliantBiome, BiomeSense and Notitia Biotechnologies.
Nexilico was founded in 2019.
Nexilico's headquarters is located in Berkeley, CA, US.
Nexilico's most recent funding round was for $275k (USD) in September 2023.
As of Sep 1, 2023, Nexilico has disclosed funding of $2M (USD). Undisclosed round amounts are excluded.
Nexilico has 4 employees as of Feb 4, 2024.
Notitia Biotechnologies
notitiabio.com
